Facioscapulohumeral Muscular Dystrophy

Facioscapulohumeral muscular dystrophy (FSHD or FSH) is characterised by muscle weakness that affects the muscles of the face, shoulders and arms and appears in adolescence or adulthood. This disease is due to a change in the structure of a small region of chromosome 4, the D4Z4 region.

 

Clinical trials ongoing at the Institute:

  • FIS-002-2019: Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
  • Resolve-RD France = Resolve Expansion: CTRN FSHD France – Prospective 18 months MRI Study
  • Advances FSHD COM = NA-FSHD: New clinical outcome measures to evaluate wheelchair-bound / non-ambulant FSHD patients

 

Acronym

FIS-002-2019

Resolve-RD France = Resolve Expansion

Advances FSHD COM = NA-FSHD

Intervention Losmapimod
Principal investigator
Teresinha Evangelista Teresinha Evangelista Teresinha Evangelista
Sponsor Fulcrum Therapeutics CHU of Nice CHU of Nice
Study status
Ongoing In preparation In preparation
Recruitment status Ongoing In preparation In preparation
Population Adult Adult Adult
  + infos on clinicaltrials.gov